With the 2% inflation rate targeted by the Federal Reserve still somewhat distant, the odds are high that, like last year, the economy and the markets would remain plagued by high borrowing costs and asset price deflation.
However, AbbVie Inc. (ABBV) looks well-placed to distinguish itself as one of the few valuable exceptions. The biopharmaceutical company develops, manufactures, commercializes, and sells medicines and therapies worldwide.
